�Nuvelo, Inc.
(Nasdaq: NUVO) announced positive results from the Phase 1b
proof-of-concept trial of NU172, demonstrating that the direct thrombin
inhibitor quickly produced and maintained anticoagulation with a rapid
come back toward baseline after the infusion over with a favorable guard
profile.
"NU172 has the potential to address many of the limitations of
currently useable anticoagulants granted the profile we
